OBJECTIVE  To evaluate the efficacy and safety of pembrolizumab combined with lenvatinib in the treatment of advanced renal cell carcinoma and advanced endometrial carcinoma.

METHODS  Searched Pubmed, EMBase, Cochrane Library, ISI Web of Science, CNKI, Wanfang database and VIP database by computer. According to the inclusion criteria and exclusion criteria, the relevant clinical randomized controlled trials of pembrolizumab combined with lenvatinib in the treatment of advanced renal cell carcinoma and advanced endometrial carcinoma were collected, and meta-analysis was performed using RevMan5.3 software.

RESULTS  A total of 4493 patients were included in 6 studies, including 1883 patients in the experimental group and 2610 patients in the control group. The results of meta-analysis showed: pembrolizumab combined with lenvatinib showed progression-free survivalHR=0.51, 95%CI(0.40, 0.64), P<0.00001, overall survivalHR=0.63, 95%CI(0.54, 0.74), P<0.00001, objective response rateRR=1.99, 95%CI(1.80, 2.21), P<0.00001 and complete response rateRR=3.11, 95%CI(1.41, 6.87), P=0.005 were significantly better than the control group, and the difference was statistically significant. In terms of safety, meta-analysis showed no statistically significant difference in grade 3 or more adverse events that occurred or worsened in the treatment of advanced renal cell carcinoma and advanced endometrial carcinomaRR=1.08, 95%CI(0.97, 1.19), P=0.14 in combination with pembrolizumab.

CONCLUSION  Pembrolizumab combined with lenvatinib has good efficacy in the treatment of advanced renal cell carcinoma and advanced endometrial carcinoma, and provides a new regimen for the treatment of advanced solid tumors.